Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

[1]  V. Heinemann,et al.  NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors , 2015, International journal of cancer.

[2]  J. Lunceford,et al.  Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. , 2015 .

[3]  C. Borg,et al.  Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer , 2014, Cancer Chemotherapy and Pharmacology.

[4]  G. Lee,et al.  A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma , 2013, Cancer Chemotherapy and Pharmacology.

[5]  F. Lordick,et al.  Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Zongguang Zhou,et al.  Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis , 2013, PloS one.

[7]  Junji Kato,et al.  A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker , 2013, Cancer Chemotherapy and Pharmacology.

[8]  P. Schlattmann,et al.  Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[10]  T. Alcindor,et al.  Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Y. Chu,et al.  CD4+Foxp3+ Regulatory T‐cell Impairment by Paclitaxel is Independent of Toll‐like Receptor 4 , 2011, Scandinavian journal of immunology.

[12]  Yi Shi,et al.  [A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer]. , 2010, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery.

[13]  D. Gilvary,et al.  A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers , 2010, Clinical Cancer Research.

[14]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[15]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[16]  F. Orsi,et al.  Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. , 2010, World journal of gastroenterology.

[17]  J. Schlom,et al.  Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement , 2008, Clinical Cancer Research.

[18]  K. Rufibach,et al.  Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Ajani,et al.  Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ajani,et al.  Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Peter C Austin,et al.  The performance of different propensity score methods for estimating marginal hazard ratios , 2007, Statistics in medicine.

[22]  J. Ajani,et al.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[24]  R. Herrmann,et al.  The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[26]  D. Cunningham,et al.  Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.

[27]  T. Yoshikawa,et al.  A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial). , 2012, Japanese journal of clinical oncology.

[28]  J. Thigpen.  Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial , 2011 .

[29]  D. Hosmer,et al.  A review of goodness of fit statistics for use in the development of logistic regression models. , 1982, American journal of epidemiology.